The ridiculously simple way to grow rich and smash the ASX200

Can you afford NOT to own ResMed Inc. (CHESS) (ASX:RMD) and Cochlear Limited (ASX:COH)?

| More on:
a woman

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The numbers don't lie.

If you really want to beat the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) and grow your wealth there is only one game in town; healthcare.

Yes, boring old healthcare.

Healthcare is bigger than Ben Hur and if you have ever questioned the need to have strong exposure to ASX-listed healthcare companies in your portfolio, this should quickly change your mind.

According to Deloitte, global healthcare spending was estimated to be worth US$7.2 trillion dollars – 10.6% of global GDP – in 2013. In relatively prosperous Australia this percentage jumps to 11.4% of national GDP.

Forget the rampant media focus on glamour industries like iron ore and banking, 11.4% of national GDP is utterly mind blowing stuff.

On steroids

But if the scale of healthcare spending is big, it is nothing compared to the performance of the big healthcare stocks over the last five years.

Just take a look at the below comparison of the S&P/ASX 200 to the S&P/ASX 200 Health Care Index (Index: ASX: XHJ):

150717 RP - ASX200 Healthcare

Source: Google Finance

Over the last five聽years the steroid injected S&P/ASX 200 Health Care Index has trumped the returns of the S&P/ASX 200 by over 100 percentage points, with annualised returns of over 20%!

The S&P/ASX 200 Health Care index is made up of 18 companies including big names like ResMed Inc. (CHESS) (ASX: RMD), Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL).

The strong returns extend to the additional eight聽companies included in the S&P/ASX 300 Health Care Index, with annualised returns over the last five years of 19.35%. But given the growing demand for healthcare products and services, a similar above-average trend is likely to reach down to the small-cap depths of the All Ordinaries Index (INDEX ASX: XAO).

Too expensive?

There is a well-founded perception that healthcare companies are expensive. In a relative sense, when compared to the broad S&P/ASX 200 Index, this is certainly is true.

The recent trailing price-to-earnings (P/E) ratio for the S&P/ASX 200 Health Care index is 26 compared to just 16.5 for the S&P/ASX 200 Index.

Meanwhile, dividend yields for聽healthcare also trail at a stingy 2%, compared to 5% for the S&P/ASX 200.

This is not to say healthcare companies are overvalued. The industry is booming and unlike many sectors has a clear, sustainable growth outlook over the next decade.

In 2013 14% of Aussies were aged 65 or older. According to the Australian Bureau of Statistics this will jump to 22% in 2061, pushing one of the key markets for healthcare products far higher and accelerating the demand for healthcare locally.

This trend is similar for developed countries around the world. As people age, it is only natural that spending on quality of life should come ahead of discretionary spending, every time.

This supports the likelihood of continued above average earnings growth for healthcare companies which will naturally command above average share prices relative to earnings today.

Low dividends allow reinvestment back into assets and research and development to ensure companies can keep up with growing demand and compound returns at high margins.

And boy, are margins high! CSL reported Group EBIT (Earnings Before Interest and Tax) margins of 29.7% in 2014, while Primary Health Care Limited's (ASX: PRY) medical centre business had a ridiculous average EBITDA margin of 56.8% in 2014.

A tick in every box

Still not convinced?

Healthcare stocks are not only growing at unparalleled rates and earning huge margins, but big companies like ResMed, CSL and Cochlear also have strong globally diversified earnings. This lowers geographic risk and amplifies returns from major currencies which are currently smoking the Aussie dollar.

The tailwinds of growing wealth in countries like China and India is only trumped by the natural tailwind of aging populations mentioned above.

Add to this this cross pollination of an industry supported by both public and private demand and we have an essential, defensive, growing, high margin and all-round formidable investment opportunity.

So let me ask you; can you afford NOT to have exposure to ASX-listed healthcare companies?

Motley Fool contributor Regan Pearson has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on 鈴革笍 Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
鈴革笍 Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
鈴革笍 Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more

asx investor daydreaming about US shares
鈴革笍 How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more

鈴革笍 Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more